Drug
Patisiran
Patisiran: highest development phase Phase 3, developed by Alnylam Pharmaceuticals. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| patisiran (ALN-TTR02) NCT01960348 | Phase 3 | TTR-mediated Amyloidosis |
| Patisiran NCT03759379 | Phase 3 | Amyloidosis, Hereditary |
| Patisiran NCT02510261 | Phase 3 | Amyloidosis |
| Patisiran NCT03862807 | Phase 3 | Amyloidosis, Familial |
| patisiran NCT05023889 | Phase 1 | Polyneuropathies |
Latest
No recent events.
Follow Patisiran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.